Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.78 |
| ▸ | HTT | P42858 | 7/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.78 |
| ▸ | LMNA | P02545 | 6/20 | 0.78 |
| ▸ | MEN1 | O00255 | 5/20 | 0.78 |
| ▸ | NPC1 | O15118 | 4/20 | 0.78 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | RECQL | P46063 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 3/20 | 0.66 |
| ▸ | JAK2 | O60674 | 1/20 | 0.64 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.64 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14907041 | 0.91 | MAPT (0.80) | MAPTKDM4EKMT2AHTTSMN1; SMN2 | |
| SCHEMBL19283293 | 0.91 | MAPT (0.80) | MAPTKDM4EKMT2AHTTSMN1; SMN2 | |
| SCHEMBL16035430 | 0.91 | MAPT (0.80) | MAPTKDM4EKMT2AHTTSMN1; SMN2 | |
| SCHEMBL28800595 | 0.90 | MAPT (0.78) | MAPTKDM4EKMT2AHTTSMN1; SMN2 | |
| SCHEMBL683795 | 0.90 | MAPT (0.86) | MAPTKDM4EKMT2AHTTSMN1; SMN2 | |
| SCHEMBL13617293 | 0.90 | MAPT (0.86) | MAPTKDM4EKMT2AHTTSMN1; SMN2 | |
| SCHEMBL28295711 | 0.88 | MAPT (0.84) | MAPTKDM4EKMT2AHTTSMN1; SMN2 | |
| SCHEMBL28800601 | 0.88 | MAPT (0.82) | MAPTKDM4EKMT2AHTTSMN1; SMN2 | |
| SCHEMBL21211449 | 0.86 | MAPT (0.73) | MAPTKDM4EKMT2AHTTSMN1; SMN2 | |
| SCHEMBL5809418 | 0.86 | KMT2A (0.80) | MAPTKDM4EKMT2AHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029403-B2 | Treatment of ovarian cancer with benzylidenebenzohydrazides | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140315959-A1 | TREATMENT OF OVARIAN CANCER WITH BENZYLIDENEBENZOHYDRAZIDES | MEMORIAL SLOAN-KETTERING CANCER CENTER | 2014-10-23 | — | — | US | disclosed |
| WO-2013071001-A1 | TREATMENT OF OVARIAN CANCER WITH BENZYLIDENEBENZOHYDRAZIDES | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315959-A1 | TREATMENT OF OVARIAN CANCER WITH BENZYLIDENEBENZOHYDRAZIDES | BRDT, BAX, BCL2 | MAPT 4837/4885KDM4E 720/4885KMT2A 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.